Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials

PURPOSE: The role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) targeted therapy for patients with EGFR-mutant non-small cell lung cancer (NSCLC) has not been clarified. A pooled analysis of prospective clinical trials was conducted to evaluate the efficacy a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Sun, Li, Guo, Yi-Jia, Song, Jun, Wang, Yan-Ru, Zhang, Shu-Ling, Huang, Le-Tian, Zhao, Jian-Zhu, Jing, Wei, Han, Cheng-Bo, Ma, Jie-Tao
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7837071/
https://ncbi.nlm.nih.gov/pubmed/33511076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.586596
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados